The world's first fully degraded blocking device system is put into clinical application

(Reporter Ding Ling Correspondent Xing Yongtian) On July 26, Pan Xiangbin, Assistant General Dean of Fuwaihua Central Vascular Disease Hospital, assistant to the dean of Fuwai Hospital of the Chinese Academy of Medical Sciences, Deputy Dean and Children of Fuwaihua Central Vascular Disease Hospital and children Fan Taibing, director of the Heart Center, applied the world's first full -block blockage system in Beijing and Zhengzhou, respectively, and successfully treated the room interval defect for three congenital heart disease children.

This is the first batch of clinical application after being approved for listing after being approved for listing.

Fan Tai Bing said that the interval variety defect is a common congenital heart disease, accounting for about 30-50%of the congenital heart disease, which seriously threatens patients' lives. At present, although the conventional intervention sealing technique has the advantages of small trauma, the sealing device implanted in the human body is made of nickel and titanium silk, which will be permanently stored in the patient's body. There may be long -term complications. And some patients have allergies to nickel ions. Developing absorbers is the key to solving the above problems.

In order to crack the bottleneck that plagues the clinical application of congenital heart disease, Hu Shengshou, an academician of the Chinese Academy of Engineering, the general dean of the Fuwai Hua Central Vascular Disease Hospital, and the director of the National Cardiovascular Disease Center, formed a composite technical team of cross -professional and interdisciplinary disciplines. Carry out basic research, and then return to clinical applications from the results of materials. After 9 years, it finally developed this absorber with completely independent intellectual property rights to fill the world gap.

The National Regional Medical Center -Fuwai China Center Vascular Disease Hospital, as the world's first main clinical research unit in the general closure system, has done a lot of basic work in clinical research and practice. During the research and development process, it not only made useful suggestions to the improvement of the conveying system, but also proposed for the first time proposed that the ultrasound guidance can be degraded through the axillary pathway to degrade the blocking of the treatment room interval defect technology. In recent years, the Fuwaihua Central Vascular Disease Hospital has launched all 23 patients in the treatment of degradable blocking device in clinical trials, which has strongly promoted the development of the system.

Fan Tai Bing said that the material of the blocking block is polyal acid, which began to be degraded slowly after a few months, decomposed into lactic acid, digested and absorbed by the human body, and generated water and carbon dioxide to discharge from the body. At the same time, the endometrial tissue will grow slowly along the blocking device. Before the blocking device is completely degraded, the human heart endometrial tissue will automatically fully supplement the house without leaving any foreign body residue.

- END -